M. Wagner, C. Redaelli, and M. Lietz, Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma, British Journal of Surgery, vol.91, issue.5, pp.586-94, 2004.
DOI : 10.1002/bjs.4484

D. Azria, M. Ychou, and W. Jacot, Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma with Combined Radiochemotherapy with 5-Fluorouracil and Cisplatin, Pancreas, vol.25, issue.4, pp.360-365, 2002.
DOI : 10.1097/00006676-200211000-00007

D. Li, K. Xie, R. Wolff, and J. Abbruzzese, Pancreatic cancer, The Lancet, vol.363, issue.9414, pp.1049-57, 2004.
DOI : 10.1016/S0140-6736(04)15841-8
URL : https://hal.archives-ouvertes.fr/hal-01262930

B. Czito, C. Willett, and J. Bendell, Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis, J Clin Oncol Int J Mol Med, vol.2411, issue.6, pp.656-62305, 2003.

H. Xiong, A. Rosenberg, and A. Lobuglio, Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms, J Clin Oncol Hum Pathol, vol.2227, issue.8, pp.2610-6119, 1996.

A. Saxby, A. Nielsen, and C. Scarlett, Assessment of HER-2 Status in Pancreatic Adenocarcinoma, The American Journal of Surgical Pathology, vol.29, issue.9, pp.1125-1159, 2005.
DOI : 10.1097/01.pas.0000160979.85457.73

N. Hynes and H. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors, Nature Reviews Cancer, vol.7, issue.5, pp.341-54, 2005.
DOI : 10.1021/jm00130a020

J. Schlessinger, Cell Signaling by Receptor Tyrosine Kinases, Cell, vol.103, issue.2, pp.211-236, 2000.
DOI : 10.1016/S0092-8674(00)00114-8

T. Kumagai, J. Davis, T. Horie, O. Rourke, D. Greene et al., The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling, Proceedings of the National Academy of Sciences, vol.98, issue.10, pp.5526-5557, 2001.
DOI : 10.1073/pnas.071060598

X. Qian, O. Rourke, D. Fei, and Z. , Domain-specific interactions between the p185(neu) and epidermal growth factor receptor kinases determine differential signaling outcomes Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3, J Biol Chem Embo J, vol.2747, issue.14, pp.574-831647, 1988.

L. Klapper, S. Glathe, and N. Vaisman, The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling, of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells, pp.4995-50001647, 1997.

D. Slamon, L. , B. Shak, and S. , Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-92, 2001.
DOI : 10.1056/NEJM200103153441101

J. Baselga, D. Pfister, and M. Cooper, Phase I studies of antiepidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [see comments], J Clin Oncol Ann Oncol Nat Med, vol.1813, issue.21, pp.904-1465, 2000.

D. Ye, J. Mendelsohn, F. Z. Kuwada, S. Scaife, C. Kuang et al., Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225 Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells Synergistic downregulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor, Oncogene Int J Cancer Proc Natl Acad Sci U S A J Clin Oncol, vol.1810910222, issue.26, pp.731-8291, 1999.

K. Chung, J. Shia, and N. Kemeny, Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma, J Clin Oncol Clin Cancer Res, vol.2311, issue.28, pp.1803-104898, 2005.

M. Dugan, S. Dergham, and R. Kucway, HER-2/neu Expression in Pancreatic Adenocarcinoma, Pancreas, vol.14, issue.3, pp.229-265, 1997.
DOI : 10.1097/00006676-199704000-00003

D. Slamon, M. Pegram, . Mf, D. Slamon, and K. Flom, Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, Semin Oncol J Clin Oncol N Engl J Med, vol.2820350, issue.32, pp.13-93095, 2001.

J. Leonard, M. Coleman, and J. Ketas, Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma, Journal of Clinical Oncology, vol.23, issue.22, pp.5044-51, 2005.
DOI : 10.1200/JCO.2005.13.821